ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib (Figure 11), the c-Abl inhibitor used to treat CML, was reported to inhibit c-Abl phosphorylation in primary neuronal cultures at micromolar levels in response to various stimuli, such as oxidative stress.